You are here

Novel Biologic Countermeasure for Acute Radiation Syndrome

Award Information
Agency: Department of Defense
Branch: Defense Health Agency
Contract: W81XWH20P0132
Agency Tracking Number: H201-002-0036
Amount: $249,971.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: DHA201-002
Solicitation Number: 20.1
Timeline
Solicitation Year: 2020
Award Year: 2020
Award Start Date (Proposal Award Date): 2020-09-24
Award End Date (Contract End Date): 2021-04-23
Small Business Information
1515 West 2200 South Suite F
Salt Lake City, UT 84119-1441
United States
DUNS: 829431076
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: Yes
Principal Investigator
 Robert Price
 (801) 915-7973
 robert@tekholding.com
Business Contact
 Mukund Karanjikar
Phone: (801) 953-1047
Email: mukund@tekholding.com
Research Institution
N/A
Abstract

Acute Radiation Syndrome (ARS) is an acute illness caused by irradiation of the entire body (or most of the body) by a high dose of penetrating radiation in a very short period of time. Global proliferation of radioactive and nuclear materials has resulted in increased threat of weaponized exposure or inadvertent exposure resulting from accidents such as Chernobyl. Presence of nuclear weapons within hostile nations combined with continued prospects of US involvement in geo-political conflicts around the world presents a real threat of ionizing radiation exposure to US Defense service personnel. It is imperative that the DOD be prepared with necessary countermeasures. A good medical countermeasure for large-scale, radiological exposure contingencies should ideally be easy to handle and to administer, stable under extreme conditions, thermoresistant, inexpensive, deployable, and must meet medical needs and therapeutic support. The medical countermeasures for ARS are broadly categorized into three classes based on the time of administration in relation to radiation exposure: radioprotectors, radiomitigators, and radiation therapeutics. While there are three FDA-approved post-exposure therapeutic drugs to treat the hematopoietic subsyndrome of ARS, there are no radioprotectors currently approved by the FDA for general human use for the prevention of ARS. We proposal a novel biologic as a radiprotector. Chemically synthesized analog of the biologic materials has demonstrated performance as a radioprotector in murine models. However, it is known that the synthetic analogs are at the most sixty percent as effective as their natural counterparts. We will produce biologically identical materials in their natural form thereby substantially improving the performance. Techno-ecoomic feasibility will be demonstrated during phase I. The work in phase II and beyond will focus on advanced animal models, GLP and GMP process development, and performing necessary tasks towards FDA IND and subsequent NDA application.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government